5 SIMPLE TECHNIQUES FOR ANTIDEPRESSANT AGENT 5

MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To judge a number of intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Primary trial aims were being To judge the protection and tolerability of sifalimumab in dermatomyositis or polymyo